Literature DB >> 22776123

Use of fenbendazole-containing therapeutic diets for mice in experimental cancer therapy studies.

Qiwen Duan1, Yanfeng Liu, Carmen J Booth, Sara Rockwell.   

Abstract

Pinworm infection (oxyuriasis) is a common problem in rodent colonies. Facility-wide prophylactic treatment of all mice with a diet containing therapeutic levels of fenbendazole for several weeks is often used to control pinworm outbreaks. We examined the effect of feeding a therapeutic diet containing 150 ppm fenbendazole on the growth of EMT6 mouse mammary tumors implanted into BALB/c Rw mice. Mice were randomized to receive either a fenbendazole-containing or control diet for 1 wk before tumor cells were injected intradermally in the flanks and throughout tumor growth. Tumor growth was monitored by serial measurements of tumor diameters from the time tumors became palpable until they reached 1000 mm3. The medicated diet did not alter tumor growth, invasion, or metastasis. When tumors reached volumes of approximately 100 mm3, some were irradiated locally with 10 Gy of X-rays. Irradiation significantly delayed tumor growth; fenbendazole did not alter the radiation-induced growth delay. However, cell culture studies showed that fenbendazole concentrations not far above those expected in the tissues of mice on this diet altered the growth of the tumor cells in culture. Recent data from other laboratories also have demonstrated effects of fenbendazole that could complicate experiments. Care should therefore be exercised in deciding whether chow containing fenbendazole should be administered to mouse colonies being used in cancer research.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22776123      PMCID: PMC3314526     

Source DB:  PubMed          Journal:  J Am Assoc Lab Anim Sci        ISSN: 1559-6109            Impact factor:   1.232


  26 in total

Review 1.  A review of treatments for the eradication of pinworm infections from laboratory rodent colonies.

Authors:  Kathleen R Pritchett; Nancy A Johnston
Journal:  Contemp Top Lab Anim Sci       Date:  2002-03

Review 2.  The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles.

Authors:  E Lacey
Journal:  Int J Parasitol       Date:  1988-11       Impact factor: 3.981

3.  Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative.

Authors:  S C Rockwell; R F Kallman; L F Fajardo
Journal:  J Natl Cancer Inst       Date:  1972-09       Impact factor: 13.506

4.  Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumors.

Authors:  Sara Rockwell; Yanfeng Liu; Helen A Seow; Kimiko Ishiguro; Raymond P Baumann; Philip G Penketh; Krishnamurthy Shyam; Oluwatoyin M Akintujoye; Peter M Glazer; Alan C Sartorelli
Journal:  Int J Radiat Biol       Date:  2011-12-20       Impact factor: 2.694

5.  A comparison of the interaction of anthelmintic benzimidazoles with tubulin isolated from mammalian tissue and the parasitic nematode Ascaridia galli.

Authors:  P J Dawson; W E Gutteridge; K Gull
Journal:  Biochem Pharmacol       Date:  1984-04-01       Impact factor: 5.858

6.  Potential radiosensitizing agents. 5. 2-Substituted benzimidazole derivatives.

Authors:  R P Gupta; C A Larroquette; K C Agrawal
Journal:  J Med Chem       Date:  1982-11       Impact factor: 7.446

Review 7.  In vivo-in vitro tumor systems: new models for studing the response of tumours to therapy.

Authors:  S Rockwell
Journal:  Lab Anim Sci       Date:  1977-10

8.  The effect of iron and protein deficiency on plasma levels and parasite uptake of [14C] fenbendazole in rats infected with Nippostrongylus brasiliensis.

Authors:  R K Prichard; J D Kelly; T D Bolin; V M Duncombe; M R Fagan
Journal:  Aust J Exp Biol Med Sci       Date:  1981-10

Review 9.  Use of hypoxia-directed drugs in the therapy of solid tumors.

Authors:  S Rockwell
Journal:  Semin Oncol       Date:  1992-08       Impact factor: 4.929

10.  scid mutation in mice confers hypersensitivity to ionizing radiation and a deficiency in DNA double-strand break repair.

Authors:  K A Biedermann; J R Sun; A J Giaccia; L M Tosto; J M Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

View more
  8 in total

1.  Biological Evaluation of a Potential Anticancer Agent Methyl N-[5-(3'-Iodobenzoyl)-1H-Benzimidazol-2-yl]Carbamate.

Authors:  Zbigniew P Kortylewicz; Don W Coulter; Janina Baranowska-Kortylewicz
Journal:  Cancer Biother Radiopharm       Date:  2019-11-05       Impact factor: 3.099

2.  An Update on the Biologic Effects of Fenbendazole.

Authors:  Carolyn Cray; Norman H Altman
Journal:  Comp Med       Date:  2022-06-28       Impact factor: 1.565

Review 3.  Double Repositioning: Veterinary Antiparasitic to Human Anticancer.

Authors:  Tania Sultana; Umair Jan; Jeong Ik Lee
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208

4.  Fenbendazole as a potential anticancer drug.

Authors:  Qiwen Duan; Yanfeng Liu; Sara Rockwell
Journal:  Anticancer Res       Date:  2013-02       Impact factor: 2.480

5.  Preliminary studies with a new hypoxia-selective cytotoxin, KS119W, in vitro and in vivo.

Authors:  Eugene Y Kim; Yanfeng Liu; Oluwatoyin M Akintujoye; Krishnamurthy Shyam; Tina A Grove; Alan C Sartorelli; Sara Rockwell
Journal:  Radiat Res       Date:  2012-08-03       Impact factor: 2.841

6.  Effect of fenbendazole on an autoimmune mouse model.

Authors:  Carolyn Cray; Toshiba Watson; Julia Zaias; Norman H Altman
Journal:  J Am Assoc Lab Anim Sci       Date:  2013       Impact factor: 1.232

7.  Preclinical studies of the Chinese Herbal Medicine formulation PHY906 (KD018) as a potential adjunct to radiation therapy.

Authors:  Sara Rockwell; Tina A Grove; Yanfeng Liu; Yung-Chi Cheng; Susan A Higgins; Carmen J Booth
Journal:  Int J Radiat Biol       Date:  2012-09-03       Impact factor: 2.694

Review 8.  The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs.

Authors:  Deok-Soo Son; Eun-Sook Lee; Samuel E Adunyah
Journal:  Immune Netw       Date:  2020-08-04       Impact factor: 6.303

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.